The chief executive of the Association of the British Pharmaceutical Industry has said there are more than 200 medicines in development to treat various stages of Alzheimer’s disease.
The ABPI statement is a response to a warning from Alzheimer’s Research UK that drugs companies may ‘retreat’ from developing new medicines.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.